All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

Background The cardiovascular risk of angiogenesis inhibitors is not well-quantified. We
hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors …

Summary Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of
docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC) …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Global health is threatened by emerging viral infections, which largely lack effective
vaccines or therapies. Targeting host pathways that are exploited by multiple viruses could …

Over the past few years, there have been considerable advances in the treatments available
to patients with metastatic or locally advanced NSCLC, particularly those who have …

Therapy for advanced non-small-cell lung cancer has developed significantly with new
awareness of histologic subtype as an important factor in guiding treatment and the …

There is an urgent need for strategies to combat dengue virus (DENV) infection; a major
global threat. We reported that the cellular kinases AAK1 and GAK regulate intracellular …

Angiogenesis is a complex biological process that plays a relevant role in sustaining the
microenvironment, growth, and metastatic potential of several tumors, including non-small …

In many cancers, including non-small cell lung cancer (NSCLC), tumor angiogenesis
pathways have been identified as important therapeutic targets. Angiogenesis is essential in …